Cardlytics, Inc. (NASDAQ:CDLX) Receives Average Recommendation of “Hold” from Analysts

Cardlytics, Inc. (NASDAQ:CDLX) has been given an average recommendation of “Hold” by the seven ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $6.92.

Several equities research analysts have commented on CDLX shares. Evercore ISI began coverage on Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 price objective on the stock. Northland Securities lowered shares of Cardlytics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $7.00 to $5.00 in a research report on Friday, August 16th. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Lake Street Capital cut Cardlytics from a “buy” rating to a “hold” rating and dropped their target price for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th.

Insider Buying and Selling

In other news, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. The trade was a 11.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Alexis Desieno sold 25,118 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the sale, the chief financial officer now owns 116,481 shares of the company’s stock, valued at $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,691 shares of company stock worth $237,767. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Banco Santander S.A. acquired a new position in Cardlytics in the first quarter valued at about $199,000. Vanguard Group Inc. grew its stake in shares of Cardlytics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock valued at $32,046,000 after buying an additional 57,805 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Cardlytics in the 1st quarter valued at $1,906,000. Price T Rowe Associates Inc. MD lifted its stake in Cardlytics by 6.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after acquiring an additional 1,774 shares in the last quarter. Finally, Perbak Capital Partners LLP acquired a new position in Cardlytics during the 1st quarter worth about $2,348,000. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Stock Performance

CDLX opened at $3.67 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics has a 12-month low of $2.89 and a 12-month high of $20.52. The firm has a 50 day moving average of $3.74 and a two-hundred day moving average of $6.16. The firm has a market capitalization of $186.51 million, a PE ratio of -0.60 and a beta of 1.61.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.18. The firm had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The firm’s revenue was down 15.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.26) earnings per share. On average, analysts anticipate that Cardlytics will post -1.52 EPS for the current year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.